PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea ("OSA"), will report its strong second ...
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the ...
SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE)-- ProSomnus Sleep Technologies ("the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today ...
ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.” — Len Liptak, CEO, ProSomnus Sleep ...
Good day, and thank you for standing by. Welcome to the ProSomnus Q4 2023 Earnings Investors Update. At this time, all participants are in listen-only mode. Please be advised that today's conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results